AURORA, ON, Jan. 23 /PRNewswire-FirstCall/ - Helix BioPharma Corp.
Helix BioPharma Corp. announces that at the Company's Annual General and Special Meeting held today, shareholders adopted all of the resolutions presented by management, most notably the election of an expanded board of directors and the approval of management's planned private placement.
Joining the Helix BioPharma board today is Dr. Gordon M. Lickrish of Ontario, a gynecological oncologist and former professor emeritus at the University of Toronto. The Helix board welcomes Dr. Lickrish as its newest member, and believes he will make an important contribution to the development of Helix's cancer therapeutics.
Helix's management would also like to thank its shareholders for their continued support, and looks forward to the continued development of the Company's new drug products, Topical Interferon Alpha-2b and L-DOS47, in the year ahead.
A Report of Voting Results in respect of the Meeting will be posted on the SEDAR website at (www.sedar.com).
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".
This document contains certain forward-looking information and statements regarding the Company's beliefs, plans and objectives. Forward-looking information and statements are not historical facts but are predictions about the future and are inherently uncertain. Forward-looking information and statements can be identified by the use of forward-looking terminology such as "looks forward", "planned", "will", or any variations thereon or comparable terminology referring to future events or results. The Company's actual results could differ materially from a conclusion, forecast or projection in its forward-looking information and statements due to a variety of risks, uncertainties and other factors, including, without limitation: uncertainty whether the Company will be able to complete any private placement on the terms proposed or at all; uncertainty whether any of the Company's proposed drug products will be successfully developed or at all; the need for future clinical trials, the occurrence and success of which cannot be assured; the need for regulatory approvals, which may not be obtained on acceptable terms or at all or may be withdrawn; research and development risks; manufacturing risks and the need to manufacture to regulatory standards; reliance by the Company on a few customers and a few suppliers; uncertainty regarding the Company's ability to generate projected sales volumes and product prices; uncertainty of the size and existence of a market opportunity for, and market acceptance of, the Company's products and those of its customers and licensees; intellectual property risks; marketing risks; partnership/strategic alliance risks and in particular, the need for performance by the Company's licensees; product liability risks; the effect of competition; the risk of unknown side effects; the Company's need for additional future capital, which may not be available in a timely manner or at all; exchange rate fluctuations; the risk of technical obsolescence; the possibility that the Company will pursue additional development projects or other business opportunities; the risk of unanticipated expenses; and other factors that are discussed or identified in the Company's latest Annual Information Form filed on SEDAR at www.sedar.com any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Forward-looking statements are based on the assumptions, beliefs, opinions and expectations of the Company's management at the time they are made, and the Company does not assume any obligation to update its forward-looking statement if those assumptions, beliefs, opinions or expectations, or other circumstances should change. For the reasons set forth above, investors should not place undue reliance on forward-looking statements. The Company does not assume any obligation to update any statement contained in this document.
Helix BioPharma Corp.CONTACT: Investor Relations, Christina Bessant, The Equicom Group Inc.,Tel: (416) 815-0700 ext. 269, (800) 385-5451, Fax: (416) 815-0080, Email:cbessant@equicomgroup.com; Media Relations, Matthew Haines, Noonan Russo,Tel: (212) 845-4235, Fax: (212) 845-4260, Email:Matthew.Haines@eurorscg.com, www.NoonanRusso.com
